JGJosé Carlos Garrido-Gracia

José Carlos Garrido-Gracia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Carlos Garrido-Gracia has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Alberto Romero-Palacios

    Hospital Universitario de Puerto Real, Cádiz, Spain

    1 shared publication
  • Alexandra Aceituno Caño

    Servicio de Medicina Interna, Hospital Universitario Torrecárdenas , Almería , Spain

    1 shared publication
  • Ana Navas

    Unidad de Inmunología y Alergia, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO) , Córdoba , Spain

    1 shared publication
  • Aurora Jurado

    Department of Immunology and Allergy, Reina Sofía University Hospital, 14004 Córdoba, Spain

    1 shared publication
  • Belén Gutiérrez-Gutiérrez

    Clinical Unit of Infectious Diseases and Microbiology, D, University Hospital VirgenMacarena, Seville, Spain

    1 shared publication
  • Carmen de la Fuente

    Unidad de Gestión Clínica de Cuidados Intensivos, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba (UCO) , Córdoba , Spain

    1 shared publication

Latest Publications

  • Open Access

    Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

    by Marta Trigo-Rodríguez, Sheila Cárcel, Ana Navas, Reinaldo Espíndola-Gómez, José Carlos Garrido-Gracia, María Ángeles Esteban Moreno, Rafael León-López, Pedro María Martínez Pérez-Crespo, Eduardo Aguilar Alonso, David Vinuesa, et al.

    The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention. The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020–March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein–1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated. One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04–0.90; P = .04). Conversely, patients with IP-10 40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.